{"id": "chatcmpl-8JZmwsWDSaDrbE4BeNfGURB1Wf95V", "object": "chat.completion", "created": 1699676494, "model": "gpt-4-0613", "choices": [{"index": 0, "message": {"role": "assistant", "content": "1. The adverse event incidence was significantly lower in the CKD-828 2.5/40 mg group.\n2. The adverse event incidence in the CKD-828 2.5/40 mg group was 9.52%.\n3. The adverse event incidence in the S-amlodipine 2.5 mg group was 27.87%.\n4. The difference in adverse event incidence between the two groups was statistically significant with a P value of 0.0086.\n5. Increasing the dose of telmisartan did not induce any unexpected adverse events.\n6. The statement suggests that CKD-828 is safe."}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 103, "completion_tokens": 135, "total_tokens": 238}, "temperature": 0, "max_tokens": 512, "top_p": 1, "frequency_penalty": 0, "presence_penalty": 0, "messages": [{"role": "system", "content": "Statement: The adverse event incidence was significantly lower in the CKD-828 2.5/40 mg (9.52%, P=0.0086) than in the S-amlodipine 2.5 mg group (27.87%) and increasing the telmisartan dose induced no unexpected adverse events, suggesting the safety of CKD-828.\n\nList all the facts we explicitly know from the statement. Make each fact as atomic as possible."}]}